April 13 (Reuters) -
* U.S. FDA OFFICIAL SAYS ONE DEATH REPORTED DUE TO RARE BLOOD CLOT AFTER J&J VACCINE, ONE PATIENT IS IN CRITICAL CONDITION
* U.S. FDA OFFICIAL SAYS HEALTH CARE PROVIDERS WHO SEE WITH EITHER A LOW BLOOD PLATELET COUNT OR BLOOD CLOTS SHOULD ESTABLISH WHETHER INDIVIDUAL HAS RECENTLY BEEN VACCINATED
* FOR PEOPLE WHO GOT J&J COVID-19 VACCINE MORE THAN A MONTH AGO, RISK OF BLOOD CLOT EVENTS IS VERY LOW AT THIS TIME- FDA OFFICIAL
* WE ARE NOT SEEING CLOTTING EVENTS WITH LOW PLATELET COUNT WITH COVID-19 VACCINES FROM PFIZER/BIONTECH AND MODERNA - CDC OFFICIAL
* U.S. FDA OFFICIAL EXPECTS PAUSE IN USE OF J&J VACCINE TO BE A "MATTER OF DAYS"
* U.S. HEALTH OFFICIAL SAYS LEADING HYPOTHESIS IS THE J&J COVID-19 VACCINE IN VERY RARE CASES IS CAUSING AN IMMUNE RESPONSE THAT LEADS TO THESE "EXTREMELY RARE" BLOOD CLOTS
* U.S. FDA OFFICIAL SAYS RECOMMENDATION TO PAUSE J&J COVID-19 VACCINE IS NOT A MANDATE
* U.S. FDA OFFICIAL SAYS UNCLEAR AT THIS TIME IF THERE IS ANY ASSOCIATION WITH ORAL CONTRACEPTIVE PILL IN INDIVIDUALS WHO HAD BLOOD CLOTS AFTER J&J VACCINE
* U.S. FDA OFFICIAL PETER MARKS DESCRIBES J&J VACCINE PAUSE AS "TEMPORARY" AND SAYS IT SHOULD NOT IMPACT OVERALL U.S. VACCINATION EFFORTS
* FDA OFFICIAL SAYS "IT'S PLAINLY OBVIOUS" THAT THE EVENTS WITH J&J COVID-19 VACCINE LOOK "VERY SIMILAR" TO CASES REPORTED IN RELATION TO ASTRAZENECA VACCINE Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.
